ArticleNeuroradiology2026
Does residual ADP reactivity within the therapeutic range predict intraoperative thromboembolic events during endovascular treatment of intracranial aneurysms?
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThromboembolic events remain one of the major complications during endovascular treatment of intracranial aneurysms. Platelet function testing is widely used to identify clopidogrel resistance, yet its role in predicting intraoperative thromboembolic complications among pharmacologically responsive patients remains unclear. This study aimed to evaluate the association between preoperative ADP-induced platelet reactivity and intraoperative thromboembolic events in patients undergoing endovascular aneurysm treatment.
methodsWe retrospectively analyzed 196 patients treated for unruptured intracranial aneurysms between March 2017 and March 2020. Patients presenting with subarachnoid hemorrhage or without available preoperative ADP values were excluded. Multiplate platelet function testing was used to measure ADP-induced platelet reactivity. Patients with ADP values > 46 AUC were considered resistant and were switched to ticagrelor or prasugrel before re-testing; resistant cases were excluded from the final analysis. Associations between preoperative ADP values and intraoperative thromboembolic complications were assessed using multivariate logistic regression.
resultsThe mean age was 55.3 ± 10.9 years, and 72.4% were female. The median preoperative ADP value was 15 (range 0-70). Intraoperative thromboembolic events occurred in 25 patients (12.8%), including material thrombus (6.6%), distal embolism (4.6%), and combined events (1.5%). Female sex was identified as an independent risk factor (OR 3.82, p = 0.045), while patients treated with a flow diverter stent had a lower risk of thromboembolic complications (OR 0.24, p = 0.029). There was no significant association between preoperative ADP reactivity and intraoperative thromboembolic events (p = 0.874).
conclusionIn this cohort of 196 patients with adequate preoperative platelet inhibition, residual ADP-induced platelet reactivity was not associated with the risk of intraoperative thromboembolic complications. These findings suggest that residual ADP reactivity within the therapeutic range has limited value for predicting intraoperative thromboembolic events.
Indexed as
Identifiers
42730834What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.